Benazza Rania, Letissier Léa, Papadakos Greg, Thom Jen, Diemer Helene, Cotton Graham, Cianférani Sarah, Hernandez-Alba Oscar
Laboratoire de Spectrométrie de Masse BioOrganique, IPHC UMR 7178, CNRS, Université de Strasbourg, 67087 Strasbourg, France.
Infrastructure Nationale de Protéomique ProFI-FR2048, 67087 Strasbourg, France.
Anal Chem. 2025 Feb 11;97(5):2639-2647. doi: 10.1021/acs.analchem.4c03323. Epub 2025 Jan 31.
Even though mAbs have attracted the biggest interest in the development of therapeutic proteins, next-generation therapeutics such as single-domain antibodies (sdAb) are propelling increasing attention as new alternatives with appealing applications in different clinical areas. These constructs are small therapeutic proteins formed by a variable domain of the heavy chain of an antibody with multiple therapeutic and production benefits compared with their mAb counterparts. These proteins can be subjected to different bioconjugation processes to form single-domain antibody-drug conjugates (sdADCs) and hence increase their therapeutic potency, and akin to other therapeutic proteins, nanobodies and related products require dedicated analytical strategies to fully characterize their primary structure prior to their release to the market. In this study, we report for the first time the extensive sequence characterization of a conjugated anti-EGFR 14 kDa sdADC by using state-of-the-art top-down mass spectrometry strategies in combination with liquid chromatography (LC-TD-MS). Mass analysis revealed a highly homogeneous sample with one conjugated molecule. Subsequently, the reduced sdADC was submitted to different fragmentation techniques, namely, higher-energy collisional dissociation, electron-transfer dissociation, and electron-transfer higher-energy collision dissociation, allowing to unambiguously assess the conjugation site with 24 diagnostic fragment ions and 85% of global sequence coverage. The sequence coverage of the nonreduced protein was significantly lower (around 16%); however, the analysis of the fragmentation spectra corroborated the presence of the intramolecular disulfide bridge along with the localization of the conjugation site. Altogether, our results pinpoint the difficulties and challenges associated with the fragmentation of sdAb-derived formats in the LC time scale due to their remarkable stability as a consequence of the intramolecular disulfide bridge. However, the use of complementary activation techniques along with the identification of specific ion fragments allows an improved sequence coverage, the characterization of the intramolecular disulfide bond, and the unambiguous localization of the conjugation site.
尽管单克隆抗体(mAb)在治疗性蛋白质的开发中引起了最大的关注,但诸如单域抗体(sdAb)等下一代治疗药物作为在不同临床领域具有诱人应用前景的新替代品,正受到越来越多的关注。这些构建体是由抗体重链可变域形成的小型治疗性蛋白质,与它们的单克隆抗体对应物相比,具有多种治疗和生产优势。这些蛋白质可以进行不同的生物偶联过程,以形成单域抗体-药物偶联物(sdADC),从而提高其治疗效力,与其他治疗性蛋白质类似,纳米抗体及相关产品在投放市场之前需要专门的分析策略来全面表征其一级结构。在本研究中,我们首次报告了通过使用最先进的自上而下质谱策略结合液相色谱(LC-TD-MS)对一种共轭抗表皮生长因子受体(EGFR)14 kDa sdADC进行的广泛序列表征。质谱分析显示该样品高度均一,只有一种共轭分子。随后,将还原后的sdADC进行不同的碎裂技术,即高能碰撞解离、电子转移解离和电子转移高能碰撞解离,从而能够通过24个诊断性碎片离子和85%的全局序列覆盖率明确评估偶联位点。未还原蛋白质的序列覆盖率显著较低(约16%);然而,对碎裂谱的分析证实了分子内二硫键的存在以及偶联位点的定位。总之,我们的结果指出了由于分子内二硫键导致的sdAb衍生形式在液相色谱时间尺度上的碎裂所带来的困难和挑战。然而,使用互补的活化技术以及特定离子碎片的鉴定能够提高序列覆盖率、表征分子内二硫键并明确偶联位点的定位。